Patrick Moser

Statistics

Publications

Citations

128

H-Index

Active since

2017

Affiliations

Comprehensive Cancer Center Vienna(Current)

Medical University of Vienna

University of Vienna

Institute of Cell Biology

Patrick Moser is an author at Comprehensive Cancer Center Vienna specializing in pharmacology, cancer pharmacology, and pharmacokinetics of anticancer drugs.

Publications per year

2017–2024

Publications

Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer

Bernhard Englinger, Sebastian Kallus, Julia Senkiv et al. · Journal of Experimental & Clinical Cancer Research · 2017 · 61 citations · Full text

Medicine, Oncology, Pharmacology +14

Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib

Bernhard Englinger, Anna Laemmerer, Patrick Moser et al. · International Journal of Cancer · 2020 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Development of a cobalt(<scp>iii</scp>)-based ponatinib prodrug system

Marlene Mathuber, Michael Gutmann, Mery La Franca et al. · Inorganic Chemistry Frontiers · 2021 · 20 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Structure–Activity Studies of 1,2,4-Oxadiazoles for the Inhibition of the NAD<sup>+</sup>-Dependent Lysine Deacylase Sirtuin 2

Arianna Colcerasa, Florian Friedrich, Jelena Melesina et al. · Journal of Medicinal Chemistry · 2024 · 12 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074

Bernhard Englinger, Sebastian Kallus, Julia Senkiv et al. · Cells · 2018 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 5